Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology

Fig. 5

Hematopoietic differentiation of the corrected hiPSCs. A Morphological changes of the corrected hiPSCs cells during hematopoietic differentiation on day 2, day 4, day 6, day 10 of OP9 co-culture. Scale bars = 200 μm. B The expression level of pluripotent markers (OCT4, SOX2 and NANOG) in corrected hiPSCs clones was analyzed on day 0, day 2, day 4, day 6, day 8, day 10 of hematopoietic differentiation. Pluripotency genes OCT4, SOX2 and NANOG gradually decreased during hematopoietic differentiation, which is approaching 0. C The expression level of germ layer gene T in corrected hiPSCs clones was analyzed on day 0, day 2, day 4, day 6, day 8, day 10 of hematopoietic differentiation. During the hematopoietic differentiation process, the germ layer gene T expression peak appeared earlier in repaired hiPSCs than that no corrected hiPSCs

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512